Advancing gene therapies for β-hemoglobinopathies with novel genome and epigenome editing tools
Charlotte Barker, Editor, BioInsights, speaks to Annarita Miccio, Group Leader, Imagine Institute of Genetic Diseases, discussing ongoing research aimed at developing gene therapies for β-hemoglobinopathies, focusing on transcriptional and epigenetic regulation. They also explore innovative tools such as CRISPR-Cas9, base editing, and epigenome editing to improve treatment safety and efficiency, with the goal of making gene therapies more accessible globally.
Institutions
- Université Paris Cité (FR)
- Institut des Maladies Génétiques Imagine (FR)
Publication Details
- Journal
- Cell and Gene Therapy Insights
- Published
- 2024-09-18
- DOI
- https://doi.org/10.18609/cgti.2024.133
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 0.00